What is HC Wainwright's Estimate for ARWR FY2025 Earnings?

Key Points

• HC Wainwright has revised its FY2025 earnings estimate for Arrowhead Pharmaceuticals to $(0.23) per share, down from $(0.20), while maintaining a "Buy" rating and price target of $80.00.
• The current consensus estimate for Arrowhead Pharmaceuticals' full-year earnings stands at $(2.42) per share, indicating significant projected losses for the coming years.
• Insider James C. Hamilton sold 15,000 shares of ARWR at an average price of $30, reducing his stake in the company by 6.07%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Monday, September 15th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($0.23) for the year, down from their prior forecast of ($0.20). HC Wainwright currently has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at ($0.38) EPS, Q1 2026 earnings at $1.83 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.23) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($3.36) EPS and FY2029 earnings at ($1.61) EPS.

Several other equities research analysts also recently commented on the company. B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Royal Bank Of Canada dropped their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Finally, TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Trading Down 2.6%

Arrowhead Pharmaceuticals stock traded down $0.82 during trading hours on Wednesday, reaching $30.69. The company had a trading volume of 4,937,943 shares, compared to its average volume of 2,707,305. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $31.67. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of -23.98 and a beta of 1.00. The company has a 50-day moving average price of $21.17 and a 200 day moving average price of $16.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analysts' expectations of $29.01 million. During the same period in the previous year, the company posted ($1.38) earnings per share.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 232,122 shares of the company's stock, valued at approximately $6,963,660. This trade represents a 6.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 40,000 shares of company stock worth $1,025,000 in the last ninety days. Company insiders own 4.30% of the company's stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 2.6% during the fourth quarter. Ameriprise Financial Inc. now owns 224,988 shares of the biotechnology company's stock worth $4,230,000 after purchasing an additional 5,732 shares in the last quarter. Captrust Financial Advisors boosted its holdings in Arrowhead Pharmaceuticals by 13.5% during the fourth quarter. Captrust Financial Advisors now owns 17,074 shares of the biotechnology company's stock worth $321,000 after purchasing an additional 2,035 shares during the last quarter. Millennium Management LLC lifted its stake in Arrowhead Pharmaceuticals by 41.7% in the fourth quarter. Millennium Management LLC now owns 914,550 shares of the biotechnology company's stock valued at $17,194,000 after acquiring an additional 268,946 shares during the last quarter. Nomura Holdings Inc. lifted its stake in Arrowhead Pharmaceuticals by 54.1% in the fourth quarter. Nomura Holdings Inc. now owns 16,466 shares of the biotechnology company's stock valued at $310,000 after acquiring an additional 5,781 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Arrowhead Pharmaceuticals by 28.3% in the fourth quarter. ProShare Advisors LLC now owns 45,330 shares of the biotechnology company's stock valued at $852,000 after purchasing an additional 10,005 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.